“We often have to rely on imaging or endoscopy to distinguish between organic and functional GI diseases but this can be expensive and invasive and does not help with the differentiation of functional GI diseases,” said AJG Co-Editor-in-Chief Paul Moayyedi, MD, FACG.
Studies in the issue address how biomarkers can play a role in the treatment of inflammatory bowel disease, liver disease, pancreatic cysts and more.
More articles on gastroenterology:
Consumerism is taking healthcare by storm: How is GI affected?
EndoChoice IPO update: Common stock price set at $15 per share
Frisbie Memorial Hospital begins to offer virtual colonoscopy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.